down arrow

Divi's Lab.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE361B01024
  • NSEID: DIVISLAB
  • BSEID: 532488
INR
5,606.50
217.65 (4.04%)
BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 6.13 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Divi's Lab.
Abbott India
Cipla
Lupin
Zydus Lifesci.
Alkem Lab
Dr Reddy's Labs
Sun Pharma.Inds.
Torrent Pharma
Aurobindo Pharma
Mankind Pharma
Why is Divis Laboratories Ltd ?
1
High Management Efficiency with a high ROE of 18.24%
2
Company has a low Debt to Equity ratio (avg) at 0 times
3
Poor long term growth as Operating profit has grown by an annual rate 8.52% of over the last 5 years
4
Positive results in Dec 24
  • PAT(HY) At Rs 1,099.00 cr has Grown at 55.67 %
  • NET SALES(HY) At Rs 4,657.00 cr has Grown at 23.72 %
  • PBDIT(Q) Highest at Rs 743.00 cr.
5
Stock is technically in a Mildly Bullish range
  • The stocks MACD and KST technical factors are also Bullish
6
With ROE of 13.4, it has a Very Expensive valuation with a 10.4 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 50.00%, its profits have risen by 49.5% ; the PEG ratio of the company is 1.4
7
High Institutional Holdings at 38.52%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
8
Market Beating Performance
  • Even though the market (BSE 500) has generated negative returns of -0.94% in the last 1 year, the stock has been able to generate 50.00% returns
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Divi's Lab. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Drugs should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Divi's Lab. for you?

Medium Risk, High Return

Absolute
Risk Adjusted
Volatility
Divi's Lab.
49.96%
1.79
27.86%
SENSEX
0.45%
0.03
14.48%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
11.48%
EBIT Growth (5y)
8.52%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.69
Tax Ratio
25.24%
Dividend Payout Ratio
49.69%
Pledged Shares
0
Institutional Holding
38.52%
ROCE (avg)
28.92%
ROE (avg)
18.24%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
69
Industry P/E
33
Price to Book Value
10.43
EV to EBIT
57.58
EV to EBITDA
49.60
EV to Capital Employed
13.78
EV to Sales
15.36
PEG Ratio
1.40
Dividend Yield
0.56%
ROCE (Latest)
21.46%
ROE (Latest)
13.38%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

17What is working for the Company
PAT(HY)

At Rs 1,099.00 cr has Grown at 55.67 %

NET SALES(HY)

At Rs 4,657.00 cr has Grown at 23.72 %

PBDIT(Q)

Highest at Rs 743.00 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 32.04%

PBT LESS OI(Q)

Highest at Rs 644.00 cr.

EPS(Q)

Highest at Rs 22.23

-1What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Divi's Lab.
Net Sales - Half Yearly
At Rs 4,657.00 cr has Grown at 23.72 %
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 743.00 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Highest at 32.04%
in the last five quarters
MOJO Watch
Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 644.00 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 589.00 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 589.00 cr has Grown at 28.3 %
over average PAT of the previous four quarters of Rs 459.00 Cr
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 22.23
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)